OBJECTIVE: Broad adoption of digital pathology (DP) is still lacking, and examples for DP connecting diagnostic, research, and educational use cases are missing. We blueprint a holistic DP solution at a large academic medical center ubiquitously integrated into clinical workflows; researchapplications including molecular, genetic, and tissue databases; and educational processes. MATERIALS AND METHODS: We built a vendor-agnostic, integrated viewer for reviewing, annotating, sharing, and quality assurance of digital slides in a clinical or research context. It is the first homegrown viewer cleared by New York State provisional approval in 2020 for primary diagnosis and remote sign-out during the COVID-19 (coronavirus disease 2019) pandemic. We further introduce an interconnected Honest Broker for BioInformatics Technology (HoBBIT) to systematically compile and share large-scale DP research datasets including anonymized images, redacted pathology reports, and clinical data of patients with consent. RESULTS: The solution has been operationally used over 3 years by 926 pathologists and researchers evaluating 288 903 digital slides. A total of 51% of these were reviewed within 1 month after scanning. Seamless integration of the viewer into 4 hospital systems clearly increases the adoption of DP. HoBBIT directly impacts the translation of knowledge in pathology into effective new health measures, including artificial intelligence-driven detection models for prostate cancer, basal cell carcinoma, and breast cancer metastases, developed and validated on thousands of cases. CONCLUSIONS: We highlight major challenges and lessons learned when going digital to provide orientation for other pathologists. Building interconnected solutions will not only increase adoption of DP, but also facilitate next-generation computational pathology at scale for enhanced cancer research.
OBJECTIVE: Broad adoption of digital pathology (DP) is still lacking, and examples for DP connecting diagnostic, research, and educational use cases are missing. We blueprint a holistic DP solution at a large academic medical center ubiquitously integrated into clinical workflows; researchapplications including molecular, genetic, and tissue databases; and educational processes. MATERIALS AND METHODS: We built a vendor-agnostic, integrated viewer for reviewing, annotating, sharing, and quality assurance of digital slides in a clinical or research context. It is the first homegrown viewer cleared by New York State provisional approval in 2020 for primary diagnosis and remote sign-out during the COVID-19 (coronavirus disease 2019) pandemic. We further introduce an interconnected Honest Broker for BioInformatics Technology (HoBBIT) to systematically compile and share large-scale DP research datasets including anonymized images, redacted pathology reports, and clinical data of patients with consent. RESULTS: The solution has been operationally used over 3 years by 926 pathologists and researchers evaluating 288 903 digital slides. A total of 51% of these were reviewed within 1 month after scanning. Seamless integration of the viewer into 4 hospital systems clearly increases the adoption of DP. HoBBIT directly impacts the translation of knowledge in pathology into effective new health measures, including artificial intelligence-driven detection models for prostate cancer, basal cell carcinoma, and breast cancer metastases, developed and validated on thousands of cases. CONCLUSIONS: We highlight major challenges and lessons learned when going digital to provide orientation for other pathologists. Building interconnected solutions will not only increase adoption of DP, but also facilitate next-generation computational pathology at scale for enhanced cancer research.
Authors: Juan Carlos Vizcarra; Erik A Burlingame; Clemens B Hug; Yury Goltsev; Brian S White; Darren R Tyson; Artem Sokolov Journal: Comput Med Imaging Graph Date: 2021-11-19 Impact factor: 4.790
Authors: Jacob Rosenthal; Ryan Carelli; Mohamed Omar; David Brundage; Ella Halbert; Jackson Nyman; Surya N Hari; Eliezer M Van Allen; Luigi Marchionni; Renato Umeton; Massimo Loda Journal: Mol Cancer Res Date: 2021-12-08 Impact factor: 6.333
Authors: Jordi Temprana-Salvador; Pablo López-García; Josep Castellví Vives; Lluís de Haro; Eudald Ballesta; Matias Rojas Abusleme; Miquel Arrufat; Ferran Marques; Josep R Casas; Carlos Gallego; Laura Pons; José Luis Mate; Pedro Luis Fernández; Eugeni López-Bonet; Ramon Bosch; Salomé Martínez; Santiago Ramón Y Cajal; Xavier Matias-Guiu Journal: Diagnostics (Basel) Date: 2022-03-30
Authors: Diana Montezuma; Ana Monteiro; João Fraga; Liliana Ribeiro; Sofia Gonçalves; André Tavares; João Monteiro; Isabel Macedo-Pinto Journal: Diagnostics (Basel) Date: 2022-02-18